Skip to main content
. 2023 Jun 8;36:11367. doi: 10.3389/ti.2023.11367

FIGURE 1.

FIGURE 1

Islet and Pancreas-After-Islet (PAI) outcomes for patients receiving CNI-sparing immunosuppression based on Belatacept (BELA) or Efalizumab (EFA). (A) Summary of beta cell replacement outcomes from time of transplant; (B) Summary of beta cell replacement outcomes by graft function status.